The burgeoning popularity of tirzepatide , initially for diabetes , is creating significant interest within the UK , prompting a notable shift in hormone trends. Availability these medications remains a complex challenge , with public healthcare system provision currently limited and private clinics offering therapy at a premium . Worries are being